Bio-Techne Receives European IVDR Certification For Diagnostic Test To Monitor Chronic Myeloid Leukemia
Portfolio Pulse from Benzinga Newsdesk
Bio-Techne has been granted European IVDR certification for its diagnostic test designed to monitor Chronic Myeloid Leukemia. This certification allows the company to market and sell the test in European markets, potentially expanding its customer base and increasing revenue from its diagnostic products segment.

March 22, 2024 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Techne's European IVDR certification for its Chronic Myeloid Leukemia diagnostic test could lead to increased market presence in Europe and potentially boost revenues from its diagnostic products segment.
Receiving the European IVDR certification is a significant regulatory milestone that allows Bio-Techne to market its diagnostic test in Europe. This expansion into European markets can lead to increased sales and revenue, particularly in the diagnostic products segment, which is crucial for the company's growth. The certification also enhances the company's reputation in the healthcare and diagnostic industry, potentially leading to further opportunities.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90